426 related articles for article (PubMed ID: 29173297)
1. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M
J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297
[TBL] [Abstract][Full Text] [Related]
2. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
3. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
4. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
[TBL] [Abstract][Full Text] [Related]
5. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
7. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
8. Extremely refractory Kawasaki disease with disseminated intravascular coagulation.
Koh YK; Lee JH; Park YB
Cardiol Young; 2017 Jul; 27(5):1004-1007. PubMed ID: 28264746
[TBL] [Abstract][Full Text] [Related]
9. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
11. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S
J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
[TBL] [Abstract][Full Text] [Related]
12. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
[No Abstract] [Full Text] [Related]
13. Infliximab plus plasma exchange rescue therapy in Kawasaki disease.
Sonoda K; Mori M; Hokosaki T; Yokota S
J Pediatr; 2014 May; 164(5):1128-1132.e1. PubMed ID: 24560183
[TBL] [Abstract][Full Text] [Related]
14. Response of refractory Kawasaki disease to intravenous methylprednisolone.
Shah I; Prabhu SS
Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
[TBL] [Abstract][Full Text] [Related]
15. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
O'connor MJ; Saulsbury FT
Clin Pediatr (Phila); 2007 May; 46(4):345-8. PubMed ID: 17475994
[TBL] [Abstract][Full Text] [Related]
16. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange.
Fujimaru T; Ito S; Masuda H; Oana S; Kamei K; Ishiguro A; Kato H; Abe J
Cytokine; 2014 Dec; 70(2):156-60. PubMed ID: 25082649
[TBL] [Abstract][Full Text] [Related]
17. Infliximab as a novel therapy for refractory Kawasaki disease.
Weiss JE; Eberhard BA; Chowdhury D; Gottlieb BS
J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313
[TBL] [Abstract][Full Text] [Related]
18. [Kawasaki disease in children--9 years experience].
Kowalczyk M; Kawalec W; Daszkowska-York J; Turska-Kmieć A; Brzezińska-Rajszys G; Sobielarska D; Ziółkowska L; Kościesza A; Jagiełłowicz D; Mirecka-Rola A
Med Wieku Rozwoj; 2005; 9(2):179-93. PubMed ID: 16085959
[TBL] [Abstract][Full Text] [Related]
19. [Kawasaki disease: what you need to know].
Bajolle F; Laux D
Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
